Crystalys Therapeutics
Recent Finacing
Series A
Recent Raise
$205M
Crystalys Therapeutics is a clinical-stage biopharmaceutical company developing dotinurad, a next-generation oral URAT1 inhibitor, to improve treatment outcomes for patients with gout.
Highlights
Focus Areas
Biopharma
Health Care
Medical
Therapeutics
Recent Investors
Financials
$205M
Total Raised
1
Funding round
13
Investors